San Diego-centered Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug industry in February after revealing promising information from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection and in March the compa